AU2759201A - Novel fgf homolog zfgf12 - Google Patents

Novel fgf homolog zfgf12

Info

Publication number
AU2759201A
AU2759201A AU27592/01A AU2759201A AU2759201A AU 2759201 A AU2759201 A AU 2759201A AU 27592/01 A AU27592/01 A AU 27592/01A AU 2759201 A AU2759201 A AU 2759201A AU 2759201 A AU2759201 A AU 2759201A
Authority
AU
Australia
Prior art keywords
zfgf12
fgf homolog
novel fgf
novel
homolog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27592/01A
Inventor
Darrell C. Conklin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of AU2759201A publication Critical patent/AU2759201A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
AU27592/01A 2000-01-05 2001-01-04 Novel fgf homolog zfgf12 Abandoned AU2759201A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47806200A 2000-01-05 2000-01-05
US09478062 2000-01-05
PCT/US2001/000238 WO2001049740A1 (en) 2000-01-05 2001-01-04 Novel fgf homolog zfgf12

Publications (1)

Publication Number Publication Date
AU2759201A true AU2759201A (en) 2001-07-16

Family

ID=23898370

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27592/01A Abandoned AU2759201A (en) 2000-01-05 2001-01-04 Novel fgf homolog zfgf12

Country Status (5)

Country Link
EP (1) EP1246843A1 (en)
JP (1) JP2003518944A (en)
AU (1) AU2759201A (en)
CA (1) CA2396401A1 (en)
WO (1) WO2001049740A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001280096B2 (en) * 2000-08-11 2007-03-22 Kyowa Kirin Co., Ltd. Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAs encoding the same

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2398603A1 (en) * 2000-02-15 2001-08-23 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
EP1947182A1 (en) * 2000-02-15 2008-07-23 Amgen Inc. Fibroblast growth factor-23 molecules and uses thereof
US20030105302A1 (en) * 2000-03-08 2003-06-05 Nobuyuki Itoh Human FGF-23 gene and gene expression products
AU2001249125A1 (en) * 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
WO2002008271A1 (en) * 2000-07-19 2002-01-31 Advanced Research & Technology Institute Novel fibroblast growth factor (fgf23) and methods for use
WO2003057733A1 (en) * 2001-12-28 2003-07-17 Kirin Beer Kabushiki Kaisha Antibodies against fibroblast growth factor 23
EP1728514A1 (en) * 2005-06-03 2006-12-06 Immunotech S.A. Uses of oligonucleotides stimulatory of the mesenchymal stem cell proliferation
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
EP4306165A3 (en) 2011-07-01 2024-04-17 NGM Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
EP2925775B1 (en) 2012-11-28 2020-09-16 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
ES2915851T3 (en) 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc FGF19 chimeric peptides for use in the treatment of bile acid disorders
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
BR112016017248A8 (en) 2014-01-24 2018-04-17 Ngm Biopharmaceuticals Inc antibody or fragment thereof, binding agent, transgenic animal, hybridoma, vector, pharmaceutical composition, fgf19 and / or fgf21-like signaling induction method, method for activating a klotho beta / fgf receptor complex, method for improving metabolism of glucose in an individual, method of detecting klotho beta, use of antibody or fragment thereof, use of pharmaceutical composition, treatment method and method for improving metabolic parameters
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
JP6949711B2 (en) 2014-10-23 2021-10-20 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Pharmaceutical composition containing peptide variant and method of use thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
EP3888672A1 (en) 2015-11-09 2021-10-06 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
JP2879148B2 (en) * 1987-07-07 1999-04-05 サイオス インコーポレイテッド Recombinant fibroblast growth factor
EP0832215A4 (en) * 1995-06-05 2000-05-17 Human Genome Sciences Inc Fibroblast growth factor 11
DE69839571D1 (en) * 1997-11-25 2008-07-10 Genentech Inc Fibroblast growth factor-19

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001280096B2 (en) * 2000-08-11 2007-03-22 Kyowa Kirin Co., Ltd. Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAs encoding the same

Also Published As

Publication number Publication date
JP2003518944A (en) 2003-06-17
EP1246843A1 (en) 2002-10-09
CA2396401A1 (en) 2001-07-12
WO2001049740A1 (en) 2001-07-12

Similar Documents

Publication Publication Date Title
AU2631001A (en) Novel fgf homolog zfgf11
AU2759201A (en) Novel fgf homolog zfgf12
AU2001262847A1 (en) Language-understanding
AU2000267458A1 (en) Hypercomputer
AU2001254546A1 (en) Aminopiperidines
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001220246A1 (en) Neckphone
AU2001258349A1 (en) Bisacylguanidine
AU2001279754A1 (en) Indoloquinazolinones
AU2001281965A1 (en) Novel 6-phenylphenanthridines
AU2001265871A1 (en) Substituted sulfonylaminopyrimidines
AU2001258924A1 (en) Microsatellite-aflp
AU2001254731A1 (en) Substituted phenyluracils
AU2001258255A1 (en) Substituted benzoylcyclohexenones
AU2001240791A1 (en) Sequence
AU2001281921A1 (en) Bdellosomes
AU2001246864A1 (en) Hypotensors
EP1201403A3 (en) Electrofusible units
AU2001262711A1 (en) Cytoprotectors
AU2001226668A1 (en) Crankshaft-starter-generator
AU2001260192A1 (en) Glycinamides
AU2002219846A1 (en) Novel use
AU2002223604A1 (en) Substituted phenyluracils
AU2001275014A1 (en) Imidazoloisoquinolines
AU2463401A (en) Novel fgf homolog zfgf10

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase